Rapid progression of amyotrophic lateral sclerosis after initiation of GLP-1 agonist: a case report

Affiliations

¹ Department of Clinical Nutrition, New York Presbyterian Hospital, New York, NY, USA and.
² Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.

Kathleen Stolwyk et al. Amyotroph Lateral Scler Frontotemporal Degener. 2025 May.

. 2025 May;26(3-4):382-384.

doi: 10.1080/21678421.2024.2446847. Epub 2025 Jan 7.

¹ Department of Clinical Nutrition, New York Presbyterian Hospital, New York, NY, USA and.
² Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.

No abstract available

Conflict of interest statement

Disclosure of interest

IL has received honorarium and consulting fees from Regeneron and Argenx Pharmaceuticals.

KS has no conflict of interest to report.

1. Andersen A, Lund A, Knop FK, Vilsboll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403. - PubMed
1. Harris E. Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable. JAMA. 2024;332(1):8. - PubMed
1. O’Reilly EJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):205–11. - PMC - PubMed
1. Mariosa D, Beard JD, Umbach DM, Bellocco R, Keller J, Peters TL, et al. Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans. Am J Epidemiol. 2017;185(5):362–71. - PMC - PubMed
1. O’Reilly EJ, Wang M, Adami HO, Alonso A, Bernstein L, van den Brandt P, et al. Prediagnostic body size and risk of amyotrophic lateral sclerosis death in 10 studies. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5–6):396–406. - PMC - PubMed